April 17, 2024 | ABBV, Daily JAM, Dividend Income |
Bookkeeping. I added AbbVie (ABBV) as Pick #10 for My New World for Dividend Investing Special Report (You can find it in the Special Report section of this site along with all the content on this market and its trends for Dividend Income investors. But I’m reposting it as a stand alone pick so no one misses it. AbbVie (ABBV) has been a long-time member of the Dividend Portfolio with a gain of 213% since my January 29, 2020 pick. The question right now is Should it be a top dividend pick going forward? After all, the appreciation in the stock has dropped the dividend yield to 3.67%. (Add in a modest yield from buybacks and the total yield goes to 4.18%.) The most pressing question has been What will replace the $20 billion in annual revenue from the company’s blockbuster arthritis drug Humira (adalimumab) now that it faces competition from biosimilar generics? Now we’ve got some numbers to answer that question and to me they add up to AbbVie remaining a top dividend pick.
October 19, 2023 | ABBV, Daily JAM, Dividend Income |
Yesterday, October 18, Abbott Laboratories (ABT) reported third-quarter 2023 adjusted earnings of $1.14 per share. That beat the Wall Street consensus projection of $1.10 a share. This was an important transitional reset quarter for Abbott
December 8, 2022 | ABBV, Daily JAM, Dividend Income, MMM |
Once a company has put in the time and money to make the Dividend Aristocrats list, the company isn’t likely to squander that investment just because a recession looms. To make the list–and garner a big chunk of cash from conservative dividend investors–a company has had to pay a dividend for a least 25 consecutive years and has had to raise that dividend every year. A company like 3M (MMM), which owns a 64-year record of paying and raising its dividend payout, is as close to a dividend sure thing as exists. Which is why it’s not surprising that AbbVie (ABBV), which owns a 50-year record of paying and raising its dividend, announced that it would raise its dividend in 2023 to $1.48 a quarter with the February 2023 payout. That would bring the annual dividend yield to 3.5% But…
June 23, 2022 | ABBV, Daily JAM, Dividend Income, GOLD, Jubak Picks, PXD, Special Reports |
The advice is sound, very sound. Move part (at least of your portfolio to cash and sit out the worst of this bear market on the sidelines. And since you have that cash in hand, you’ll be ready to snap up bargains when the market has put in a bottom (or near the bottom, or on the way up from the bottom…or something.) But right now that’s easier said than done.
May 14, 2022 | ABBV, BMY, Daily JAM, MRK, PFE |
I can’t find Big Pharma stock in the green during Friday’s big rally. Which makes me question the staying power of Friday’s move. If the day’s gains were the result of a market bottom, wouldn’t everything be up? Even the very defensive drug stocks? Not as much as the tech losers of 2022 but still if the market had bottomed I’d expect these stocks to be in the green too. More evidence, I think, for my thesis that Friday was the result of technical trading in an over-sold market.
April 25, 2022 | AAPL, ABBV, AMZN, BMY, CMG, Daily JAM, FB, GOOG, Morning Briefing, MSFT, PYPL |
Going into this earnings season, the hope was that strong, surprisingly strong perhaps, earnings from the big growth stocks would put a stop to the selling. Earnings would be strong enough to convince investors that the market wasn’t over-valued since at these growth rates stocks would be seen to be quick growing into current extended valuations That hasn’t exactly worked so far. But this week the earnings story from growth stocks hits its stride. If the companies reporting this week can’t make the case for growth stock earnings, there probably isn’t a growth stock story to be made in the light of Federal Reserve interest rate increases, supply chain disruptions, and fears of a recession.
February 11, 2020 | ABBV, Daily JAM, Stock Alerts |
Shares of AbbVie (ABBV) tacked on another 1.32% today to a close at $96 continuing a run that began back on January 31 at $81.02. The trend picked up momentum on February 7 after the company reported fourth quarter earnings with better than expected sales for its...
January 28, 2020 | ABBV, Daily JAM, Stock Alerts |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
